Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LAVA-1207 by LAVA Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
LAVA-1207 is under clinical development by LAVA Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Risk adjusted net present value: What is the current valuation of LAVA Therapeutics's LAVA-1207?
LAVA-1207 is a monoclonal antibody commercialized by LAVA Therapeutics, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer...
Risk adjusted net present value: What is the current valuation of LAVA Therapeutics's LAVA-1207?
LAVA-1207 is a monoclonal antibody commercialized by LAVA Therapeutics, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer...